N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists
申请人:Terricabras Belart Emma
公开号:US20090130090A1
公开(公告)日:2009-05-21
New antagonists of the interaction between the CCR1 Chemokine receptor and its ligands, including MIP-1α (CCL3), represented by formula (I) are disclosed, as well as pharmaceutical compositions comprising them and their use in therapy for the treatment of pathological conditions or diseases susceptible of being improved by antagonism of the CCR1 receptor.
N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS
申请人:Almirall, S.A.
公开号:EP1891064B1
公开(公告)日:2009-09-02
[EN] N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS<br/>[FR] DERIVES AMIDE N DE 8-AZABICYCLO[3.2.1]OCT-3-YLE UTILISES COMME ANTAGONISTES CCR1
申请人:ALMIRALL PRODESFARMA SA
公开号:WO2006133802A1
公开(公告)日:2006-12-21
[EN] The present invention relates to new antagonists of the interaction between the CCR1 Chemokine receptor and its ligands, including MIP-1a (CCL3), in particular new N-amide derivatives of 8-azabicyclo[3.2.1]oct-3-yl of formula (I). [FR] La présente invention concerne de nouveaux antagonistes de l'interaction entre le récepteur de chémokine CCR1 et ses ligands, y compris MIP-1a (CCL3), en particulier de nouveaux dérivés amide N de 8-azabicyclo[3.2.1]oct-3-yle de la formule (I).